LPAR1 and systemic sclerosis: Recent evidence from in vitro studies or animal models as well as pre-clinical observations has proved the contribution of LPA to the pathogenesis of SSc or organ fibrosis, suggesting that LPA receptor (LPA1) antagonists may be effective in the treatment of SSc (116–119).